BEXBACH, GERMANY – 29th April 2026 – O3 Holding GmbH (the Company), the holding company of KD Pharma Group, announces today that Oscar Groet, Chief Executive Officer of KD Pharma Group has decided to step down from his role as CEO. Accordingly, he has been removed by the Company’s shareholders' meeting as managing director of the Company and has been released from his corporate functions with effect as of 29th April 2026. The company thanks Oscar for his contributions and leadership and wishes him all the best in his future endeavours. The Company appreciates his dedication and the efforts he has made for KD Pharma Group. Adam Ismail (Chief Commercial Officer of KD Pharma Group) and Thomas Strauch (Chief Financial Officer of KD Pharma Group) have been appointed as interim Co-CEOs and jointly lead the Company and KD Pharma Group effective April 29, 2026.
ABOUT KD PHARMA GROUP
The KD Pharma Group is a CDMO that creates health solutions in the pharmaceutical and nutraceutical space. It is also the worldwide leading producer Omega-3 fatty acids for the pharmaceutical and nutraceutical markets, formulation and encapsulation services, with over 700 employees and a presence in the UK, Norway, Germany, Switzerland, Canada, Peru and the US. The KD Pharma Group employs state-of-the-art technology which is protected by numerous patents. Visit www.kdpharmagroup.com to learn more.
IMPORTANT INFORMATION
This release contains forward-looking statements. These statements are based on plans, estimates and projections currently available to KD Pharma Group. Forward-looking statements therefore speak only as of the date they are made. KD Pharma Group assumes no obligation to update or develop such statements in light of new information or future events. By their nature, forward-looking statements involve risks and uncertainties. A variety of important factors could cause actual results to differ materially from those in forward-looking statements.